Remove 2002 Remove Clinical Trials Remove Consumption Remove Medicine
article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

In time, Western civilization caught on, and consumption expanded around the globe. Using integration or psychotherapy along with these medicines allows patients to incorporate the positive effects permanently. Comparing psychedelics: dosing and consumption information. Now, psychedelic research is booming.

History 119
article thumbnail

New Study: Demographic and policy-based differences in behaviors and attitudes towards driving after marijuana use: an analysis of the 2013–2017 Traffic Safety Culture Index

Cannabis Law Report

The authors share this view, assessing that the current evidence shows that marijuana can impair driving ability and increase crash risk, especially shortly after consumption. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. A meta-analysis by Asbridge et al. JAMA Pediatr. 2017;171:142–9.

Policy 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Focusing on professional medical publications, this study sought to investigate how medicinal cannabis is being represented in professional medical publications. The precis is simple. Background. Conclusions. Background.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.